

Recommendations for Pneumococcal Vaccine Use in Children

Table 1. Recommended Schedules for Administering Pneumococcal Conjugate Vaccine (PCV)

Child's age now	Vaccination history of PCV7 and/or PCV13	Recommended PCV13 Schedule (For minimum interval guidance for catch-up vaccination, see *)
2 through 6 months	0 doses	3 doses, 8 weeks* apart; 4th dose at age 12–15 months
	1 dose	2 doses, 8 weeks* apart; 4th dose at age 12–15 months
	2 doses	1 dose, at least 8 weeks* after the most recent dose; 4th dose at age 12–15 months
7 through 11 months	0 doses	2 doses, 8 weeks apart*; 3rd dose at age 12–15 months
	1 or 2 doses before age 7 months	1 dose at age 7–11 months; 2nd dose at age 12–15 months, at least 8 weeks after the most recent dose
12 through 23 months	0 doses	2 doses, at least 8 weeks apart
	1 dose before age 12 months	2 doses, at least 8 weeks apart
	1 dose at or after age 12 months	1 dose, at least 8 weeks after the most recent dose
	2 or 3 doses before age 12 months	1 dose, at least 8 weeks after the most recent dose
	4 doses of PCV7 or other age-appropriate complete PCV7 schedule	1 PCV13 dose, at least 8 weeks after the most recent PCV7 dose
24 through 59 months (healthy)	Unvaccinated or any incomplete schedule	1 dose, at least 8 weeks after the most recent dose
	4 doses of PCV7 or other age-appropriate complete PCV7 schedule	1 dose, at least 8 weeks after the most recent dose
24 through 71 months (with risk factor described in Table 3 below)	Unvaccinated or any incomplete schedule of less than 3 doses	2 doses, one at least 8 weeks after the most recent dose and another dose at least 8 weeks later
	Any incomplete schedule of 3 doses	1 PCV13 dose, at least 8 weeks after the most recent PCV7 dose
	4 doses of PCV7 or other age-appropriate complete PCV7 schedule	1 PCV13 dose, at least 8 weeks after the most recent PCV7 dose
6 through 18 years with immunocompromising condition, functional or anatomic asplenia (see specific conditions in Table 3 below), cerebrospinal fluid leak, or cochlear implant	Unvaccinated or any history of PCV7 or PPSV23	Consider 1 dose of PCV13

* Minimum interval between doses: For children younger than age 12 months: 4 weeks; for children age 12 months and older: 8 weeks.

Table 2. Recommended Schedule for Administering Pneumococcal Polysaccharide Vaccine (PPSV23) to Children

Risk Group	Schedule for PPSV23	Revaccination with PPSV23
Immunocompetent children with risk condition (see Table 3 below)	Give 1 dose of PPSV23 at age 2 years or older and at least 8 weeks after last dose of PCV	Not indicated
Children with immunocompromising condition, functional or anatomic asplenia (see specific conditions in Table 3 below)	Give 1 dose of PPSV23 at age 2 years or older and at least 8 weeks after last dose of PCV	Give 1 additional dose of PPSV23 at least 5 years following the first PPSV23; no more than 2 PPSV23 doses are recommended in a lifetime

Table 3. Underlying Medical Conditions that Are Indications for Pneumococcal Vaccination Among Children

Risk Group	Condition
Immunocompetent children	Chronic heart disease (particularly cyanotic congenital heart disease and cardiac failure); chronic lung disease (including asthma if treated with prolonged high-dose oral corticosteroids); diabetes mellitus; cerebrospinal fluid leak; cochlear implant
Children with functional or anatomic asplenia	<ul style="list-style-type: none"> Sickle cell disease and other hemoglobinopathies Congenital or acquired asplenia, or splenic dysfunction
Children with immunocompromising conditions	<ul style="list-style-type: none"> HIV infection Chronic renal failure and nephrotic syndrome Diseases associated with treatment with immunosuppressive drugs or radiation therapy (e.g., malignant neoplasms, leukemias, lymphomas, and Hodgkin disease; or solid organ transplantation) Congenital immunodeficiency (includes B- [humoral] or T-lymphocyte deficiency; complement deficiencies, particularly C1, C2, C3, or C4 deficiency; and phagocytic disorders [excluding chronic granulomatous disease])